Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. uri icon

authors

  • Pujade-Lauraine, Eric
  • Pignata, Sandro
  • Friedlander, Michael
  • Colombo, Nicoletta
  • Harter, Philipp
  • Fujiwara, Keiichi
  • Ray-Coquard, Isabelle
  • Banerjee, Susana
  • Liu, Joyce
  • Lowe, Elizabeth S
  • Bloomfield, Ralph
  • Ledermann, Jonathan A
  • Pautier, Patricia
  • Selle, Frédéric
  • Gebski, Val
  • Penson, Richard T
  • Oza, Amit M
  • Korach, Jacob
  • Huzarski, Tomasz
  • Poveda, Andrés

publication date

  • January 1, 2017